AKL Therapeutics > About AKL > Key Advisors

AKL’s business model is led by a small group of executives accessing expert opinion to guide corporate strategy and product development

These key advisors are recognised experts in their field and used extensively to guide AKL’s corporate, preclinical and clinical strategy.

Strategy:

Dr. Annalisa Jenkins OBE
Former Executive VP and Global Head Research & Development Merck Serono, SVP and Head of Global Medical Affairs BMS. Linkedin

Preclinical:

Prof. Frank Bonner
Former Director of Science & Technology, Huntingdon Life Sciences. Former President of British Toxicology Society. Linkedin

Manufacturing:

John McCrerie
Former Technical Director of Becpharm Limited; Senior Manager and International QA Director Wellcome Glaxo